142 related articles for article (PubMed ID: 32772232)
41. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
[TBL] [Abstract][Full Text] [Related]
42. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
43. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
44. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
[TBL] [Abstract][Full Text] [Related]
45. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
46. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
47. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
48. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
Fizazi K; Oldenburg J; Dunant A; Chen I; Salvioni R; Hartmann JT; De Santis M; Daugaard G; Flechon A; de Giorgi U; Tjulandin S; Schmoll HJ; Bouzy J; Fossa SD; Fromont G
Ann Oncol; 2008 Feb; 19(2):259-64. PubMed ID: 18042838
[TBL] [Abstract][Full Text] [Related]
49. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis.
van Dijk MR; Steyerberg EW; Habbema JD
Eur J Cancer; 2006 May; 42(7):820-6. PubMed ID: 16574403
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
51. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
52. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcome of chemotherapy for advanced testicular and extragonadal germ cell tumors: a single-center 27-year experience.
Tanaka T; Kitamura H; Takahashi A; Masumori N; Tsukamoto T
Jpn J Clin Oncol; 2010 Jan; 40(1):73-8. PubMed ID: 19773268
[TBL] [Abstract][Full Text] [Related]
54. Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience.
Kamel MH; Littlejohn N; Cox M; Eltahawy EA; Davis R
J Endourol; 2016 May; 30(5):510-9. PubMed ID: 26669219
[TBL] [Abstract][Full Text] [Related]
55. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
56. [Medical treatment of metastatic germ cell cancers].
Timsit MO; Lebret T; Lugagne PM; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S376-81. PubMed ID: 19070818
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: an Izmir Oncology Group (IZOG) study.
Salman T; Yildiz E; Yildiz I; Yavuzer D; Unlu M; Varol U; Akyol M; Yildiz Y; Bayoglu V; Kucukzeybek Y; Alacacioglu A
J BUON; 2015; 20(4):1054-60. PubMed ID: 26416056
[TBL] [Abstract][Full Text] [Related]
58. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
59. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Bokemeyer C
Eur J Cancer; 2018 May; 94():16-25. PubMed ID: 29505967
[TBL] [Abstract][Full Text] [Related]
60. Improved survival of poor-risk non-seminomatous germ cell tumor patients: real-world data from a single institute in Japan.
Tanuma K; Kawai K; Nitta S; Shiga M; Kawahara T; Negoro H; Onozawa M; Inoue T; Nishiyama H; Miyazaki J
Jpn J Clin Oncol; 2023 Jan; 53(1):74-79. PubMed ID: 36151048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]